Extracellular Matrix Structures
A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.
1 . A tissue prosthesis, comprising:
a remodelable sheet structure comprising a first sheet layer, a second sheet layer, and a physiological sensor, said physiological sensor being disposed between said first and second sheet layers,
said first sheet layer comprising a first top surface and a first bottom surface, said second sheet layer comprising a second top surface and a second bottom surface,
said first sheet layer comprising a first extracellular matrix (ECM) composition comprising first decellularized ECM derived from a first mammalian tissue source,
said second sheet layer comprising a second extracellular matrix (ECM) composition comprising second decellularized ECM derived from a second mammalian tissue source,
said first and second sheet layers, when delivered to damaged tissue, being adapted to reduce an inflammatory phase of said damaged tissue and induce host tissue proliferation, bioremodeling and, thereby, neovascularization of said damaged tissue, and regeneration of tissue structures,
said first and second sheet layers being joined, wherein said first sheet layer first bottom surface is in communication with said second sheet layer second top surface, and said physiological sensor is encased by said first and second sheet layers.
2 . The tissue prosthesis of claim 1 , wherein said first mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.
3 . The tissue prosthesis of claim 1 , wherein said first ECM composition comprises at least a first additional biologically active agent.
4 . The tissue prosthesis of claim 3 , wherein said first biologically active agent comprises a growth factor selected from the group consisting of a basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF).
5 . The tissue prosthesis of claim 1 , wherein said second mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.
6 . The tissue prosthesis of claim 1 , wherein said second ECM composition comprises at least a second additional biologically active agent.
7 . The tissue prosthesis of claim 6 , wherein said second biologically active agent comprises a growth factor selected from the group consisting of bFGF, TGF-β and VEGF.
8 . The tissue prosthesis of claim 1 , wherein said first and second sheet layers are joined via a microneedle structure.